Shares of Intuitive Surgical plunged to $372.50, down 4.2% from Thursday's close and roughly 7.5% in after-hours trading, despite a Q2 report that topped Wall Street expectations across the board. The company reported an 11.83% EPS beat, revenue up 18.54% to $2.89 billion, and non-GAAP gross margin expanding to 70.0% from 67.9% a year ago. The sell-off crystallizes a painful reality for shareholders: in a market punishing expensive healthcare stocks, even excellent results aren't enough.
The Numbers Beat; the Stock Didn't Care. Q2 revenue was $2.89 billion, up 19% year-over-year from $2.44 billion — well above the analyst consensus of roughly $2.81–$2.83 billion.
Worldwide procedure volume grew approximately 16%, with the company's robotic-assisted surgeries up ~15% and its newer lung-biopsy platform up ~36%. Yet the stock had already shed 30% year-to-date entering the print, driven by valuation compression and tariff concerns rather than any fundamental deterioration. The post-earnings drop shows the bar for a recovery wasn't just "beat" — it was "blow away and raise."
Tariffs and Margins Remain the Real Anxiety. Management raised full-year gross margin guidance to 68.0%–69.0%, directly countering fears about cost pressures from its newest surgical platform. Still, the company has estimated tariffs will drag roughly 1% of revenue due to global sourcing, and the forward price-to-earnings ratio of ~36.7x remains well above the medical equipment sector average of 25.4x. Investors are demanding a steeper discount for that uncertainty.
The Upgrade Cycle Is Real, But Priced In. Intuitive placed 468 systems in Q2, including 246 of its newest-generation robots — up from 180 a year ago.
Hospitals using the newer platform run it roughly 11% more than its predecessor , which feeds the recurring revenue stream — instruments and accessories — that accounts for over 80% of total sales. That's a powerful growth engine, but history warns: Q1's initial +7.16% earnings pop faded to a -9.41% decline over 30 days.
What Comes Next for a $138 Billion Stock at a 52-Week Low. ISRG touched its 52-week low of $378.50 this week, versus a high of $603.88.
Bank of America's target sits at $520, Barclays at $651 — implying 40–75% upside. The disconnect between analyst conviction and market price suggests the stock is trapped between strong fundamentals and a macro environment that refuses to reward premium valuations until tariff clarity emerges.